ARQT Arcutis Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARQT

Price (delayed)

$21.85

Market cap

$2.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.03

Enterprise value

$2.81B

?
Relative Growth: Rel. Growth: 76
Relative Strength: Rel. Strength: 59
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 62

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent ...

Highlights
ARQT's gross profit has surged by 101% year-on-year and by 11% since the previous quarter
Arcutis Biotherapeutics's net income has surged by 98% YoY and by 85% QoQ
Arcutis Biotherapeutics's quick ratio has decreased by 28% YoY and by 20% QoQ
Arcutis Biotherapeutics's debt has increased by 3.5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://arcutis.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ARQT

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
2.34%
1 week
1.91%
1 month
-6.98%
1 year
64.66%
YTD
-24.76%
QTD
-7.26%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$415.62M
Gross profit
$377.98M
Operating income
$3.21M
Net income
-$2.38M
Gross margin
90.9%
Net margin
-0.6%
The company's operating income has surged by 126% QoQ and by 103% YoY
The operating margin has soared by 124% from the previous quarter and by 101% YoY
ARQT's gross profit has surged by 101% year-on-year and by 11% since the previous quarter
Arcutis Biotherapeutics's net margin has surged by 99% YoY and by 86% QoQ

Price vs fundamentals

How does ARQT's price correlate with its fundamentals

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
14.29
P/S
6.8
EV/EBIT
232.88
EV/EBITDA
199.99
EV/Sales
6.77
ARQT's EPS has soared by 97% YoY and by 77% QoQ
The stock's price to book (P/B) is 86% more than its 5-year quarterly average of 7.5 but 8% less than its last 4 quarters average of 15.1
Arcutis Biotherapeutics's equity has increased by 33% YoY
The company's revenue has surged by 95% YoY and by 11% QoQ
The price to sales (P/S) is 16% lower than the last 4 quarters average of 7.9

Efficiency

How efficient is Arcutis Biotherapeutics business performance
The company's return on invested capital has surged by 112% YoY
ARQT's ROS has soared by 106% YoY
ARQT's return on assets has surged by 98% year-on-year and by 86% since the previous quarter
The ROE has soared by 98% YoY and by 86% from the previous quarter

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 70% greater than its total liabilities
The total liabilities has increased by 34% YoY and by 11% from the previous quarter
ARQT's total assets is up by 34% year-on-year and by 6% since the previous quarter
Arcutis Biotherapeutics's debt is 40% lower than its equity
Arcutis Biotherapeutics's equity has increased by 33% YoY
ARQT's debt to equity is down by 23% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.